SCHEMBL4643246

SCHEMBL4643246

Cc1ncc(N)c(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30193964 1.00
SCHEMBL558953 0.75
SCHEMBL2116759 0.75
SCHEMBL788493 0.75
SCHEMBL29676892 0.75
SCHEMBL7246171 0.75
SCHEMBL3712628 0.75
SCHEMBL850260 0.75
SCHEMBL28084504 0.73 CSNK1A1 (0.42)
SCHEMBL13202779 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250206722-A1 SMALL MOLECULE INHIBITORS OF TEA DOMAIN FAMILY MEMBERS THE SCRIPPS RESEARCH INSTITUTE 2025-06-26 US disclosed
CN-119403551-A Small molecule inhibitors of TEA domain family members 斯克里普斯研究学院 2025-02-07 CN disclosed
US-20240327406-A1 POTASSIUM CHANNEL MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2024-10-03 US disclosed
CN-117751119-A Potassium channel modulators 奥蒂福尼疗法有限公司 2024-03-22 CN disclosed
US-20230310428-A1 EGFR INHIBITOR AND PREPARATION METHOD AND USE THEREOF Hongyun Biotech Co., Ltd. (CN) 2023-10-05 US disclosed
WO-2023029833-A1 SOS1 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海海和药物研究开发股份有限公司 2023-03-09 WO disclosed
WO-2023017263-A1 POTASSIUM CHANNEL MODULATORS AUTIFONY THERAPEUTICS LIMITED (GB) 2023-02-16 WO disclosed
CN-108774214-A Heterocyclic amides as kinase inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2018-11-09 CN disclosed
CN-106488919-B 3-substituted 2-aminoindole derivatives 武田药品工业株式会社 2018-10-23 CN disclosed
CN-105209443-B Indoleamine 2, 3-dioxygenase (IDO) inhibitors 百时美施贵宝公司 2018-08-07 CN disclosed
US-20120238575-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES MERCK SERONO SA (CH) 2012-09-20 US disclosed
CN-102066384-A Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands BRISTOL MYERS SQUIBB CO 2011-05-18 CN disclosed
CN-101981031-A Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them TAKEDA PHARMACEUTICAL 2011-02-23 CN disclosed
US-20080287474-A1 Antiproliferative Pyrimidyl, Fused Pyrimidyl and Pyrimidyl Hydrazones LABORATOIRES SERONO SA (CH) 2008-11-20 US disclosed
EP-1957469-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES Laboratoires Serono SA (CH) 2008-08-20 EP disclosed
CN-101035780-A Substituted nitrogen-containing six-membered amino-heterocycles as vanilloid-1 receptor antagonists for treating pain MERCK SHARP & DOHME (GB) 2007-09-12 CN disclosed
WO-2007065940-A1 ANTIPROLIFERATIVE PYRIMIDYL, FUSED PYRIMIDYL AND PYRIMIDYL HYDRAZONES LABORATOIRES SERONO S.A. (CH) 2007-06-14 WO disclosed
CN-1226166-A Formulations and methods for treating congestive heart failure ELI LITTY AND COMPANY (US) 1999-08-18 CN disclosed
CN-1194140-A Medicine LILLY CO ELI (US) 1998-09-30 CN disclosed
CN-1145226-A Method for treating substance abuse withdrawal LILLY CO ELI (US) 1997-03-19 CN disclosed